巨子生物：2025 年上半年业绩：自营运利润（OP）因管理费用率改善高于预期；维持买入评级

28 August 2025 | 2:23AM HKT Giant Biogene Holding (2367.HK) Earnings review: 1H25 sales/NI inline with OP beat on better managed ROI; Guidance unchanged; Buy 2367.HK 12m Price Target: HK$71.00 Price: HK$54.85 Upside: 29.4% | | 12/24 | 12/25E | 12/26E | 12/27E | | --- | --- | --- | --- | --- | | Revenue (Rmb mn) New | 5,538.8 | 6,920.8 | 8,782.7 | 10,406.4 | | Revenue (Rmb mn) Old | 5,538.8 | 6,933.6 | 8,787.7 | 10,360.5 | | EBITDA (Rmb mn) | 2,331.1 | 2,698.1 | 3,331.7 | 3,896.8 | | EPS (Rmb) New | 2.10 | 2 ...